PharmiWeb.com - Global Pharma News & Resources
15-Dec-2023

Global Canine Flu Therapeutics Industry to hit US$ 3.06 Billion by 2033, driven by a 4.1% CAGR | FMI

The global canine flu therapeutics industry is expected to grow at a CAGR of 4.1% from 2023 to 2033, reaching a value of US$ 3.06 billion by 2033, while the market is likely to reach a value of US$ 2.04 billion in 2023. The market is driven by a number of factors, including the rising prevalence of canine flu, increasing pet humanization, and growing awareness of the importance of canine healthcare.

Canine flu is a highly contagious respiratory illness caused by influenza A viruses. It is transmitted through direct contact with an infected dog or through respiratory droplets. The virus can also survive on surfaces for up to 48 hours, making it easy for dogs to become infected.

Discover Our Expert Analysis with Our Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-4315

Symptoms of canine flu can include fever, cough, runny nose, lethargy, and loss of appetite. In severe cases, the virus can cause pneumonia and death. Most dogs recover from canine flu within two to three weeks, but some may develop chronic lung problems.

There is no specific treatment for canine flu. Treatment is typically supportive and includes rest, fluids, and medications to relieve symptoms. Antibiotics may be prescribed to prevent secondary bacterial infections.

The canine flu therapeutics market is expected to grow steadily in the coming years. This growth is being driven by a number of factors, including:

  • Rising prevalence of canine flu: The prevalence of canine flu is increasing worldwide. This is due to a number of factors, including increased travel by dogs, more dogs being housed in kennels and shelters, and the emergence of new strains of the virus.
  • Increasing pet humanization: Pet humanization is the trend of treating pets like members of the family. This trend is leading to increased spending on pet healthcare, including the treatment of canine flu.
  • Growing awareness of the importance of canine healthcare: Pet owners are becoming more aware of the importance of canine healthcare. This is leading to increased demand for veterinary services, including the treatment of canine flu.

Key Takeaways:

  • The rising pet humanization trend is one of the key drivers of the canine flu therapeutics market. Pet owners are increasingly considering their pets as family members and are willing to spend more on their health and well-being.
  • The higher penetration of dog flu around the world is another factor driving the growth of the market. Canine flu is a highly contagious respiratory infection that can affect dogs of all ages and breeds.
  • The advent of new dog healthcare research and treatment facilities is also contributing to the growth of the market. These facilities are developing new and innovative treatments for canine flu, which is further boosting the demand for canine flu therapeutics.
  • The market is segmented by drug type into antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and antiviral drugs. Antibiotics are the most widely used drug type in the treatment of canine flu, followed by NSAIDs and antiviral drugs.
  • The market is also segmented by distribution channel into veterinary hospitals, retail pharmacies, and online pharmacies. Veterinary hospitals are the primary distribution channel for canine flu therapeutics, followed by retail pharmacies and online pharmacies.

Reach Out To Our Analyst For Prompt Assistance With Your Questions! https://www.futuremarketinsights.com/ask-question/rep-gb-4315

Key players in the canine flu therapeutics market include:

  • Interver Inc
  • Merck Animal Health
  • al Health
  • GlaxoSmithKline Plc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Pfizer Inc.
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.

Key Segments Covered:

By Drug Class:

  • Antibiotics
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Antiviral Drugs

By Distribution Channel:

  • Veterinary Clinics
  • Veterinary Pharmacies
  • Online Pharmacies

Key Regions Covered:

  • North America
  • Latin America
  • Europe
  • Japan
  • Asia Pacific Excluding Japan
  • The Middle East and Africa

Elevate Your Brand: Explore the Insights from Our Customization Report! https://www.futuremarketinsights.com/customization-available/rep-gb-4315

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: 
sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

Editor Details

Last Updated: 15-Dec-2023